A New Milestone in Hepatitis C Treatment
Datuk Dr Muhammad Radzi Abu Hassan, National Head of Gastroenterology and Hepatology, Ministry of Health | Jean-Michel Piedagnel, Director, Drugs for Neglected Diseases Initiative (DNDi) Southeast Asia
You can share this podcast by copying this HTML to your clipboard and pasting into your blog or web page.
Earlier this month, Malaysia’s Drug Control Authority granted conditional registration of a new drug to treat hepatitis C. This move was hailed by many as another step towards eliminating hepatitis C, making treatment both more affordable and accessible in low- and middle-income countries like Malaysia. Why was this hailed as a new milestone and how long will it take before we achieve a hepatitis-free world? We find out from Datuk Dr Muhammad Radzi Abu Hassan, National Head of Gastroenterology and Hepatology, Ministry of Health, and Jean-Michel Piedagnel, Director, Drugs for Neglected Diseases Initiative (DNDi) Southeast Asia.
Image source: Shutterstock
Produced by: Lim Sue Ann
Presented by: Tee Shiao Eek
This and more than 60,000 other podcasts in your hand. Download the all new BFM mobile app.
Categories: Health Policy, Diseases & Conditions, Mental Health, Healthy Living, Fitness, Medical Innovation and Technology, Science
Tags: The Bigger Picture, Health & Living, hepatitis C, HCV, Ravidasvir, Sofosbuvir, disease elimination, Drugs For Neglected Disease Initiative, DNDi, antivirals, direct-acting antivirals,